Close

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Industry Reports
Typography

Peregrine Pharmaceuticals, Inc announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

The quarterly dividend on the Series E Preferred Stock is payable on July 1, 2016 to holders of record at the close of business on June 17, 2016.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from April 1, 2016 through June 30, 2016. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a company focused on continued revenue growth from its contract manufacturing business and developing its novel immuno-oncology products.  The company is working to evaluate its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers.  Peregrine's in-house cGMP manufacturing capabilities are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.

Contacts:

Jay Carlson
(800) 987-8256
This email address is being protected from spambots. You need JavaScript enabled to view it.
Peregrine Pharmaceuticals, Inc.

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
This email address is being protected from spambots. You need JavaScript enabled to view it.

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok